Analysis Predictors of the Outcome of Adjuvant of Hormone Therapy on Estrogen Receptor-positive Breast Cancer in Indonesia
DOI:
https://doi.org/10.3889/oamjms.2021.6683Keywords:
Breast cancer, Outcome, Recurrence, Recurrent free survivalAbstract
BACKGROUND: An existing study reported variation of the outcome of adjuvant hormone therapy on breast cancer.
AIM: This study aimed to examine predictors of the hormone therapy to the outcome of recurrence-free survival (RFS) of estrogen receptor-positive (ER+) breast cancer.
METHODS: In this cohort study, we followed up 219 eligible breast cancer patients with ER+ who had hormone therapy in 2017–2018. Age of patients, cancer stage, and various histopathology parameters were collected from the medical records, then we followed up with the patients within 2 years (2019–2020) to assess the RFS outcome. Bivariate analysis was conducted to assess the association between the clinicopathology parameters with RFS outcome. Multivariate analysis with logistic regression was also performed to see the dominant predictor. Mediation path analysis was also performed to determine the estimated effect of a predictor on the level of RFS and to see the visualization of the association of predictors with RFS.
RESULTS: Breast cancer RFS was 91.3% within 2 years of hormone therapy. The recurrent rate was only 8.7%, which most of them (68.4%) were local. There was no association of age, lymphovascular invasion (LVI), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status with RFS. Based on the molecular subtype, the RFS was better in luminal A (p = 0.045), and also better gradually in the lower stage (p = 0.001). Multivariate analysis shows that the cancer stage was the dominant predictor of the RFS outcome (p = 0.001) with OR = 4.271 (Exp[B] = 1.937–9.417). Mediation analysis also found that there was a positively associated molecular subtype with RFS through cancer stage mediation (r = 16.7%, p = 0.006) but no statistically significant association of age, LVI, PR, and HER2 status (p > 0.005).
CONCLUSION: Cancer stage is the main predictor of RFS of hormone therapy outcome. Luminal A is most also likely to have a better outcome of RFS, especially mediated by the lower stage.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492 PMid:30207593 DOI: https://doi.org/10.3322/caac.21492
Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer. 2019;11:151-64. https://doi.org/10.2147/bctt.s176070 PMid:31040712 DOI: https://doi.org/10.2147/BCTT.S176070
Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: Burden and trends. Cancer Epidemiol Biomarkers Prev. 2017;26(4):444-57. https://doi.org/10.1158/1055-9965.epi-16-0858 PMid:2822343 DOI: https://doi.org/10.1158/1055-9965.EPI-16-0858
National Cancer Institute. Cancer Stat Facts: Female Breast Cancer Subtypes; 2020. Available from: https://www.seer.cancer.gov/statfacts/html/breast-subtypes.html. [Last accessed on 2021 Feb 20]. https://doi.org/10.32388/7sm165 DOI: https://doi.org/10.32388/7SM165
Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181-5. https://doi.org/10.1111/his.14091 PMid:32056259 DOI: https://doi.org/10.1111/his.14091
Nishimura R, Osako T, Nishiyama Y, Nakano M, Fujisue M, Toyozumi Y, et al. Evaluation of factors related to late recurrence-later than 10 years after the initial treatment-in primary breast cancer. Oncology. 2013;85(2):100-10. https://doi.org/10.1159/000353099 PMid:23867253 DOI: https://doi.org/10.1159/000353099
Harahap WA, Nindrea RD. Prognostic Factors of local-regional recurrence in patients with operable breast cancer in Asia: A meta-analysis. Open Access Maced J Med Sci. 2019;7(4):690-5. https://doi.org/10.3889/oamjms.2019.151.151 PMid:30894935 DOI: https://doi.org/10.3889/oamjms.2019.151
National Cancer Institute. Breast Hormone Therapy Fact Sheet. Available from: https://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet. [Last accessed on 2021 Feb 20]. https://doi.org/10.1037/e533512012-001 DOI: https://doi.org/10.1037/e533512012-001
Davey MG, Ryan EJ, McAnena PF, Boland MR, Barry MK, Sweeney KJ, et al. Disease recurrence and oncological outcome of patients treated surgically with curative intent for estrogen receptor positive, lymph node negative breast cancer. Surg Oncol. 2021;37:101531. http://doi.org/10.1016/j.suronc.2021.101531 PMid:33545657 DOI: https://doi.org/10.1016/j.suronc.2021.101531
Rugo HS, Finn RS, Gelmon K, Joy AA, Harbeck N, Castrellon A, et al. Progression-free survival outcome is independent of objective response in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with palbociclib plus letrozole compared with letrozole: Analysis from PALOMA-2. Clin Breast Cancer. 2020;20(2):e173-80. https://doi.org/10.1016/j.clbc.2019.08.009 PMid:31836434 DOI: https://doi.org/10.1016/j.clbc.2019.08.009
De-Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, et al. Evaluation of the predictive role of tumor immune infiltrate in patients with her2-positive breast cancer treated with neoadjuvant anti-HER2 therapy without chemotherapy. Clin Cancer Res. 2020;26(3):738-45. https://doi.org/10.1158/1078-0432.ccr-19-1402 PMid:31653641 DOI: https://doi.org/10.1158/1078-0432.CCR-19-1402
Izci H, Tambuyzer T, Tuand K, Depoorter V, Laenen A, Wildiers H, et al. A systematic review of estimating breast cancer recurrence at the population level with administrative data. J Natl Cancer Inst. 2020;112(10):979-88. https://doi.org/10.1093/jnci/djaa050 PMid:32259259 DOI: https://doi.org/10.1093/jnci/djaa050
Schunkert EM, Zhao W, Zänker K. Breast cancer recurrence risk assessment: Is non-invasive monitoring an option? Biomed Hub. 2018;3(3):1-17. https://doi.org/10.1159/000492929 PMid:31988964 DOI: https://doi.org/10.1159/000492929
Lafourcade A, His M, Baglietto L, Boutron-Ruault M, Dossus L, Rondeau V, et al. Factors associated with breast cancer recurrences or mortality and dynamic prediction of death using history of cancer recurrences: The French E3N cohort. BMC Cancer. 2018;18(1):171. https://doi.org/10.1186/s12885-018-4076-4 PMid:29426294 DOI: https://doi.org/10.1186/s12885-018-4076-4
Salvo E, Ramirez AO, Cueto J, Law EH, Situ A, Cameron C, et al. Risk of recurrence among patients with HR-positive, HER2- negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis. Breast. 2021;57:5-17. https://doi.org/10.1016/j.breast.2021.02.009 PMid:33677313 DOI: https://doi.org/10.1016/j.breast.2021.02.009
Van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marmé F, et al. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Res Treat. 2018;167(1):59-71. https://doi.org/10.1007/s10549-017-4480-5 PMid:28875243 DOI: https://doi.org/10.1007/s10549-017-4480-5
Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to V. J Clin Oncol. 2016;34(9):927-35. https://doi.org/10.1200/jco.2015.62.3504 PMid:26786933 DOI: https://doi.org/10.1200/JCO.2015.62.3504
Geurts YM, Witteveen A, Bretveld R, Poortmans PM, Sonke GS, Strobbe LJ, et al. Patterns and predictors of first and subsequent recurrence in women with early breast cancer. Breast Cancer Res Treat. 2017;165(3):709-20. https://doi.org/10.1007/s10549-017-4340-3 PMid:28677011 DOI: https://doi.org/10.1007/s10549-017-4340-3
Li Y, Lu S, Zhang Y, Wang S, Liu H. Loco-regional recurrence trend and prognosis in young women with breast cancer according to molecular subtypes: Analysis of 1099 cases. World J Surg Oncol. 2021;19:113. https://doi.org/10.21203/rs.3.rs-62351/v2 PMid:33849563 DOI: https://doi.org/10.21203/rs.3.rs-62351/v2
He XM, Zou DH. The association of young age with local recurrence in women with early-stage breast cancer after breast-conserving therapy: A meta-analysis. Sci Rep. 2017;7:11058. https://doi.org/10.1038/s41598-017-10729-9 PMid:28894168 DOI: https://doi.org/10.1038/s41598-017-10729-9
Lee MK, Varzi LA, Chung DU, Cao M, Gornbein J, Apple SK, et al. The effect of young age in hormone receptor positive breast cancer. Biomed Res Int. 2015;2015:325715. https://doi.org/10.1155/2015/325715 PMid:26351632 DOI: https://doi.org/10.1155/2015/325715
Yu NY, Iftimi A, Yau C, Tobin NP, van ‘t Veer L, Hoadley KA, et al. Assessment of long-term distant recurrence-free survival associated with tamoxifen therapy in postmenopausal patients with luminal a or luminal B breast cancer. JAMA Oncol. 2019;5(9):1304-9. https://doi.org/10.1001/jamaoncol.2019.1856 PMid:31393518 DOI: https://doi.org/10.1001/jamaoncol.2019.1856
Downloads
Published
How to Cite
License
Copyright (c) 2020 Hardisman Dasman, Wirsma Arif Harahap, Daan Khambri (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
